Skip to main content

Novel vaccine generation for the treatment of cancer. A glyco-nanomedial approach instructing T cells

Objective

There is an urgent need to develop vaccines for the induction of CD8+ T-cell immunity to treat cancer and infectious diseases. Dendritic Cells (DC) have shown potential to induce antigen specific CD8+ T-cell responses with the help of CD4+ T cells, yet the efficacy by which the induction is achieved still has its limitations. The main challenge is: (a) to increase targeting efficacy to the complete repertoire of DC subsets; (b) to trigger T-cell responses by the DC that is powerful enough to eliminate a tumour (c) to implement novel human read-out systems, that mimic he human body response to evaluate vaccine efficacy.

The aim of this research project is to develop new glycan-based nanomedicines targeted to DC to induce powerful T-cell responses. Within the scope of this research project these new glycan-based nanomedicines will be tested to (i) trigger a strong T-cell response to pathogens, (ii) induce a powerful and adequate T-cell response to self antigen in a tumour induced immune suppressive environment and (iii) render fundamental insights to establish a vaccine platform relevant for the treatment of cancer and infectious diseases.

GlycoTreat employs an unconventional, novel glycan biotechnology approach to target a multitude of DC subsets in the human skin to validate the groundbreaking hypothesis that the local administration and molecular size and glycan valency of the targeting compound affect the efficiency of the T-cell stimulating vaccine. This research project joins the chemical design of glyco-nanomedical vaccines with immunological outcomes in our advanced in-vitro, in-situ human skin and in-vivo mouse DC model systems. While crossing the established disciplinary boundaries between chemistry, biology and medicine, Prof. van Kooyk will generate a new field of expertise in vaccine development applied in the field of cancer treatment.

Field of science

  • /medical and health sciences/health sciences/infectious disease
  • /medical and health sciences/medical biotechnology/nanomedicine
  • /medical and health sciences/clinical medicine/oncology/cancer
  • /medical and health sciences/basic medicine/pharmacology and pharmacy/pharmaceutical drug/vaccines

Call for proposal

ERC-2013-ADG
See other projects for this call

Funding Scheme

ERC-AG - ERC Advanced Grant

Host institution

STICHTING VUMC
Address
De Boelelaan 1117
1081 HV Amsterdam
Netherlands
Activity type
Research Organisations
EU contribution
€ 2 498 736
Principal investigator
Yvette Van Kooyk (Prof.)
Administrative Contact
Yvette Van Kooyk (Mrs.)

Beneficiaries (2)

STICHTING VUMC
Netherlands
EU contribution
€ 2 498 736
Address
De Boelelaan 1117
1081 HV Amsterdam
Activity type
Research Organisations
Principal investigator
Yvette Van Kooyk (Prof.)
Administrative Contact
Yvette Van Kooyk (Mrs.)
STICHTING VU

Participation ended

Netherlands
Address
De Boelelaan 1105
1081 HV Amsterdam
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Yvonne Koppelman (Mrs.)